“BACTERIOPHAGE THERAPY” AN EMERGING CURE FOR BACTERIAL DISEASE
DOI:
https://doi.org/10.22159/ijcpr.2023v15i5.3056Keywords:
Bacteriophages, Viruses, Life cycle, Bacterial parasites, Phage therapy, Transcytosis, Phage resistance, Phage delivery, Superhost immune responseAbstract
Bacteriophages are viruses that infect bacterial cells and have been explored for their potential in treating bacterial infections. This review discusses the taxonomy of bacteriophages and the safety concerns in phage therapy. Although bacteriophages were initially considered safe for humans and animals, recent research indicates potential interactions with eukaryotic cells, raising questions about safety. Nevertheless, successful phage therapy cases have been reported, showing promising results in treating biofilm-based and multidrug-resistant infections. The use of bacteriophages has demonstrated minimal side effects and appears to be a viable alternative to traditional antibiotics. However, more research and controlled clinical trials are needed to fully understand the efficacy and safety of phage therapy in various clinical settings.
Downloads
References
Dąbrowska K, Abedon ST. Pharmacologically aware phage therapy: pharmacodynamic and pharmacokinetic obstacles to phage antibacterial action in animal and human bodies. Microbiol Mol Biol Rev. 2019;83(4):e00012-19. doi: 10.1128/MMBR.00012-19, PMID 31666296.
Podlacha M, Grabowski L, Kosznik Kawsnicka K, Zdrojewska K, Stasiłojc M, Węgrzyn G. Interactions of bacteriophages with animal and human organisms-safety issues in the light of phage therapy. Int J Mol Sci. 2021 Aug 19;22(16):8937. doi: 10.3390/ijms22168937, PMID 34445641.
Gorski A, Miedzybrodzki R, Wegrzyn G, Jonczyk Matysiak E, Borysowski J, Weber Dabrowska B. Phage therapy: current status and perspectives. Med Res Rev. 2020;40(1):459-63. doi: 10.1002/med.21593, PMID 31062882.
Blanco Picazo P, Fernandez Orth D, Brown Jaque M, Miro E, Espinal P, Rodriguez Rubio L. Unravelling the consequences of the bacteriophages in human samples. Sci Rep. 2020;10(1):6737. doi: 10.1038/s41598-020-63432-7, PMID 32317653.
Miernikiewicz P, Dąbrowska K, Piotrowicz A, Owczarek B, Wojas Turek J, Kicielinska J. T4 phage and its head surface proteins do not stimulate inflammatory mediator production. Plos One. 2013;8(8):e71036. doi: 10.1371/journal.pone.0071036, PMID 23976975.
Nguyen S, Baker K, Padman BS, Patwa R, Dunstan RA, Weston TA. Bacteriophage transcytosis provides a mechanism to cross epithelial cell layers. mBio. 2017;8(6):e01874-17. doi: 10.1128/mBio.01874-17, PMID 29162715.
Lehti TA, Pajunen MI, Skog MS, Finne J. Internalization of a polysialic acid-binding Escherichia coli bacteriophage into eukaryotic neuroblastoma cells. Nat Commun. 2017;8(1):1915. doi: 10.1038/s41467-017-02057-3, PMID 29203765.
Ramirez Sanchez C, Gonzales F, Buckley M, Biswas B, Henry M, Deschenes MV. Successful treatment of Staphylococcus aureus prosthetic joint infection with bacteriophage therapy. Viruses. 2021;13(6):1182. doi: 10.3390/v13061182, PMID 34205687.
Grabowski L, Węgrzyn G, Węgrzyn A, Podlacha M. Highly different effects of phage therapy and antibiotic therapy on immunological responses of chickens infected with Salmonella enterica serovar Typhimurium. Front Immunol. 2022;13:956833. doi: 10.3389/fimmu.2022.956833, PMID 36211337.
Zhvania P, Hoyle NS, Nadareishvili L, Nizharadze D, Kutateladze M. Phage therapy in a 16 y boy with netherton syndrome. Front Med (Lausanne). 2017;4:94. doi: 10.3389/fmed.2017.00094, PMID 28717637.
Rezk N, Abdelsattar AS, Elzoghby D, Agwa MM, Abdelmoteleb M, Aly RG. Bacteriophage as a potential therapy to control antibiotic-resistant Pseudomonas aeruginosa infection through topical application onto a full-thickness wound in a rat model. J Genet Eng Biotechnol. 2022;20(1):133. doi: 10.1186/s43141-022-00409-1, PMID 36094767.
Johri AV, Johri P, Hoyle N, Pipia L, Nadareishvili L, Nizharadze D. Case report: chronic bacterial prostatitis treated with phage therapy after multiple failed antibiotic treatments. Front Pharmacol. 2021;12:692614. doi: 10.3389/fphar.2021.692614, PMID 34177601.
Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant acinetobacter baumannii infection. Antimicrob Agents Chemother. 2017;61(1):e00954-17.
Paul K, Merabishvili M, Hazan R, Christner M, Herden U, Gelman D. Bacteriophage rescue therapy of a vancomycin-resistant Enterococcus faecium infection in a one-year-old child following a third liver transplantation. Viruses. 2021;13(9):1785. doi: 10.3390/v13091785, PMID 34578366.
Cano EJ, Caflisch KM, Bollyky PL, Van Belleghem JD, Patel R, Fackler J. Phage therapy for limb-threatening prosthetic knee lebsiella pneumoniae infection: case report and in vitro characterization of anti-biofilm activity. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2021;73(1):e144-e151. doi: 10.1093/cid/ciaa705, PMID 32699879.
Wu N, Dai J, Guo M, Li J, Zhou X, Li F, Gao Y, Qu H, Lu H, Jin J, Li T, Shi L, Wu Q, Tan R, Zhu M, Yang L, Ling Y, Xing S, Zhang J, Yao B, Le S, Gu J, Qin J, Cheng M, Tan D, Li L, Zhang Y, Zhu Z, Cai J, Song Z, Guo X, Chen LK, Zhu T. Pre-optimized phage therapy on secondary Acinetobacter baumannii infection in four critical covid-19 patients. Emerging Microbes and Infections. 2021;10(1):612-8. doi: 10.1080/22221751.2021.1902754, PMID 33703996.
Published
How to Cite
Issue
Section
Copyright (c) 2023 TEJASV GUPTA, KANCHAN, SAMEER S. BHAGYAWANT
This work is licensed under a Creative Commons Attribution 4.0 International License.
